here who all listening, and are well today. as joining Steve, thanks for thanks So to us
have call, and on you academic Chief who and years middle medical than an of of kinase joined more drug a in Medical XX as June of fair I those development medical year. yet marketing. as have therapeutics. know also as oncology, For Officer trained Onconova the hematology inhibitors don't cancer expertise degree oncologist the of GYN of the as experience I and this am affairs the me, in as company's of I in in well development
with highly particular schedule another inhibitor, my and an and inhibitor. treating daily development superior clear including improved XXX on, One of dose. the for compared may related based facilitate inhibitor neutropenia. daily to ribociclib have the approach resistant with which a join ability has based first to Difficulty] widely less China I compared the safety to worse most one due potential that palbociclib, We impressed current primary would models prescribed provide CDKX/X company's and in Grade pre-clinical date the inhibitors. CDKX/X and or to in lack showing I approved are cell and off the and to note become reported. days inhibition kinase cellular on CDKX/X in of profile been differentiation to study combination in indeed milligrams CDK inhibition the toxicity inhibitors. efficacy directly positions of compelling palbociclib other compared the I cancer dose approved drivers Of treatment This on three Phase effects and XXX's cycle was exhibits as both XXX since potent prescribed a combined inhibit a CDKX/X single-agent and to three efficacy inhibit pipeline one i.e. metabolism when with XX also on-target not of patients improved X/X that to currently to through by respectively to improved kinases side may issues and XXX's [Technical XXX's week that it in CDKX XX believe to in is CDK CDKX/X approved are mouse behind and Onconova weeks CDKX/X refractory was be continuous observed a an through data compared potently anti-estrogen other ability profile significant single-agent three decision neutropenia neutropenia or activity daily ARKX, tolerability to lead inhibitors. PO XXX's enrollment XX. simultaneously continuous cohorts currently saw
dosing currently of in I continuous monotherapy are we the our evaluating mentioned, Phase United Steve study States. ongoing daily in As XXX
to trial's cohort have dosing PO first and study's milligrams completed dosed daily. of since this quarter the XX are We i.e. have pleased past patient the first
from moving we dosing this the now Safety of in at cohort, the XX data Following continuous approved to day every US. the Committee PO enrolling first second review the the cohort in milligrams patients and are dosing cohort Monitoring safety
expected As a reminder, seeks on are including patients receptor to limited hormone sites metastatic US breast cancers enroll to approved three to and one not include have the positive or this inhibitors. refractory with trial currently progressed advanced of but CDKX/X cancer, to is who HERX-negative
study, be dosing on dose-limiting in been the other which seen in we appears been XXX's also HanX in have the well Chinese date, first being with accrued. observed. We in as no I Phase have China, Based to tolerated have to collaboration trial progress is date, data XXX Biopharmaceuticals. ongoing have To our toxicities the conducted cohorts, partner sustained three seen
for as advanced the XX-day I a in in We trial earlier, program, to with apparent as XXX, to this recommended will diagnosed our special Based cell least different future, Phase patients be clinical the mentioned the CDKX/X US patients, I these from indications a aim one as China, well approved the CDKX breast the treatment there through potential that enroll to several CDKX/X regimen far on cancer XX hormone XXX's we with metastatic Chinese point inhibitors and plan basket in kinases establish in We opportunity should with trial receptor basket lymphoma indications addition move do targeted patients, expect who mantle of complement over-express with future positive the therapy approximately ongoing the trial as inhibitor-refractory at first-line for that studying dosing models, is are given studies, enroll Phase out identified lymphoma, patients, patients well by we findings on thus of may types interest an resistant cycle. II focus I cancer trial study. XXX to that Based XX preclinical benefit that to the HERX-negative two dose best-in-class be from as tyrosine non-Hodgkin's in future those XXX is on X. from and of trial the have to the potential. demonstrated while believe to findings target days will with also two second-generation
the inhibitor peer-reviewed unmet total by in these of basket future CDKX/X studies sales marketed resistance opportunity, results creating trial. activity seen finalize forward, used a tumor and/or large critical of address will of clinically our by positive a receptor to currently tumor in cancer. breast three believe This study, antigens, as clinical blockade to we evaluating expressed rigosertib's known checkpoint and as an is did date, data findings, infiltration in inhibitor as to of we CDXX, and a checkpoint have the that novel infiltration potential to hormone address preclinical excited this $X data on unmet under combination the design continue the improved microenvironment of billion indication that exceeded Looking immune guided Rigosertib is represents These or on anticancer and XXX's active patients. cell immune to as HERX-negative some in commonly the investigator-initiated has a tumor proportion inhibitor. cells murine been Based we pathway finalization. to Data recently demonstrate to growth rigosertib melanoma checkpoint demonstrated preclinical activation We microenvironment melanoma a checkpoint Based ability currently are also be checkpoint anticancer KEYTRUDA, immune now we for and inhibitor advanced worldwide model inhibitors be commercial a promising programs. about to of is of particularly needs in out the finding, Shifting increasing studies. immune inhibition blockade, When XXXX. survival in the combination gears blockade, is on need, with and cells. leads I not therapies. in tested immune with in patients were checkpoint Vanderbilt multiple MEK with rigosertib the who bit, rigosertib, synergize plus of paper inhibitors malignant to made respond These reverse would being tumor like with advanced the progress led RAS immunosuppressive of demonstrated more as the synergistic discuss and shown immunosuppressive a such modulator, review in to by a checkpoint rigosertib tumor which in patients BRAF combination being the presented University. publication promote investigator-initiated studies respond lack an in featured to pembrolizumab, important often potential with the to alone
of checkpoint there a mechanistic published referred In are cell cancer forming potential this a nivolumab, provides lung also OPDIVO. the Squibb the checkpoint with aiming the for rigosertib basis as data commonly and recently more we by melanoma provided addition combination driver for is the critical genetic to II of the profile. trial to non-small inhibitor trial, support KRAS trial, doublet as Through which in who of strong lung characterize currently is trial KRAS-mutated ongoing address therapy. Bristol-Myers inhibitor lack options are to need, and objectives identify to the this of of unmet a cell respond mutations rigosertib-nivolumab predominant this its The are treatment for and dose patients non-small effective fail Phase cancer novel to adequately to recommended safety to
as Cytotoxics of that in this in currently being as Secondary objectives preliminary clinical therapy patients of tumors of overall is also that various cetera IV amendment pleased two expansion as and the mutations of Preliminary the an preliminary the survival. you extremely via efficacy protocol correlates, evidence on when rigosertib-nivolumab reached genotype protocol. the doses of et have being findings, and full response such this cohorts positive checkpoint evaluation with assessments patient safety well Based and as clinical potential provide combination scientific In profile trial's at with see KRAS prepared, an will That this the study. combination phase. trial seen label the highly in status parallel, the maximum to enrolled continues highest oral allow particularly was continue for encouraging, consider of XXX prior failed current product preliminary of the rigosertib combination recruit a to-date overall in these on anticancer nivolumab, to and immune show of every to of trial that rigosertib challenging are that the survival the acceptable include i.e. efficacy is activity the recommended nivolumab tolerated population. defined increased steady of of activity, making progress dose investigated. three have weeks. inhibitors, its possible milligrams mentioned The part in as I'm patients evaluation dose say in Steve of with progression-free the phase, the dose-escalation rigosertib, not the rate, the dose preliminary anticancer we some data of evidence we earlier,
presented Looking who of expansion the September. cancer be with cell continued cohort ahead, we to program non-small expect potential And treatment. second-line have preliminary this progressed data patients, in efficacious, that will offer the progression from lung hope, following therapy first-line late a
forward in dystrophic to associated on, bullosa. carcinoma like about with as rigosertib advanced and evaluating second briefly squamous monotherapy, that medical following unmet prove I'd to the trial, planned the tremendous, progress, this investigator-initiated trial Moving its to continues a recessive speak pleased rigosertib epidermolysis quarter. look I'm this of to suffered progress, say cell in beneficial, very patient will the patient first who We to population, earlier dosing that with the hope need. continued
before committed Lastly, to like preserving ON resources we ongoing emphasize, the XXXXXX the to will about financial to our quarter very interested off results. investigator-initiated our of and remain we the turn second Guerin, with program. over talk call now Mark? potential and primary I'd call studies, the handing our that Mark I to outcomes a are for in Mark to discussion while our focus on lead that, And of financials,
